Angela A. Armstrong

Array ( [id] => 16199871 [patent_doc_number] => 10725026 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-28 [patent_title] => Method for predicting risk of exposure to interstitial fibrosis and tubular atrophy with clusterin [patent_app_type] => utility [patent_app_number] => 15/810861 [patent_app_country] => US [patent_app_date] => 2017-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 3815 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15810861 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14993737 [patent_doc_number] => 20190315826 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => Method for Increasing the Secretion Levels of Interleukin 2 and Proteins Derived from it [patent_app_type] => utility [patent_app_number] => 16/461258 [patent_app_country] => US [patent_app_date] => 2017-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4955 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16461258 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19339333 [patent_doc_number] => 12049511 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-30 [patent_title] => Engineered CD46-specific effector cells and uses thereof in the treatment of cancer [patent_app_type] => utility [patent_app_number] => 16/349258 [patent_app_country] => US [patent_app_date] => 2017-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 21 [patent_no_of_words] => 20595 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 368 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16349258 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12219222 [patent_doc_number] => 20180057582 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-01 [patent_title] => 'METHODS OF TREATMENT OF EOSINOPHILIC BRONCHITIS WITH AN ANTI-IL-5 ANTIBODY' [patent_app_type] => utility [patent_app_number] => 15/804104 [patent_app_country] => US [patent_app_date] => 2017-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 8288 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15804104 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13481745 [patent_doc_number] => 20180292415 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-11 [patent_title] => METHODS PREDICTING RISK OF AN ADVERSE CLINICAL OUTCOME [patent_app_type] => utility [patent_app_number] => 15/800512 [patent_app_country] => US [patent_app_date] => 2017-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15698 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15800512 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12786472 [patent_doc_number] => 20180153993 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES [patent_app_type] => utility [patent_app_number] => 15/789853 [patent_app_country] => US [patent_app_date] => 2017-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13917 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15789853 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12184079 [patent_doc_number] => 20180043015 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'SUBSTANCES, VACCINES AND METHODS FOR DIAGNOSING AND REDUCING INCIDENCES OF TRANSPLANT REJECTION' [patent_app_type] => utility [patent_app_number] => 15/789752 [patent_app_country] => US [patent_app_date] => 2017-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 20080 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15789752 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12790834 [patent_doc_number] => 20180155447 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => METHODS FOR TREATING CARDIOVASCULAR DISEASES [patent_app_type] => utility [patent_app_number] => 15/788604 [patent_app_country] => US [patent_app_date] => 2017-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19847 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15788604 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12657070 [patent_doc_number] => 20180110856 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-26 [patent_title] => Pharmaceutical Formulations and Methods of Making the Same [patent_app_type] => utility [patent_app_number] => 15/788762 [patent_app_country] => US [patent_app_date] => 2017-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13187 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15788762 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14743885 [patent_doc_number] => 20190255116 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => KIT FOR PREPARING DISEASE-TREATING AGENT, DISEASE-TREATING AGENT AND METHOD FOR PREPARING DISEASE-TREATING AGENT [patent_app_type] => utility [patent_app_number] => 16/343330 [patent_app_country] => US [patent_app_date] => 2017-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11768 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16343330 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16268835 [patent_doc_number] => 20200270322 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => NOVEL INTERLEUKIN 4 IMMUNOCONJUGATES [patent_app_type] => utility [patent_app_number] => 16/341644 [patent_app_country] => US [patent_app_date] => 2017-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20052 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16341644 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17385629 [patent_doc_number] => 20220033481 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => COMPOSITIONS AND METHODS FOR INCREASING PROTEIN HALF-LIFE IN A SERUM [patent_app_type] => utility [patent_app_number] => 16/755268 [patent_app_country] => US [patent_app_date] => 2017-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14619 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16755268 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15946047 [patent_doc_number] => 10660902 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-26 [patent_title] => Method of increasing satellite cell proliferation with an HDAC inhibitor [patent_app_type] => utility [patent_app_number] => 15/728476 [patent_app_country] => US [patent_app_date] => 2017-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 63 [patent_no_of_words] => 35741 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15728476 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15454509 [patent_doc_number] => 20200040079 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-06 [patent_title] => HLA-RESTRICTED VGLL1 PEPTIDES AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/339981 [patent_app_country] => US [patent_app_date] => 2017-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19946 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -49 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16339981 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12158877 [patent_doc_number] => 20180030141 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-01 [patent_title] => 'CX3CR1-BINDING POLYPEPTIDES' [patent_app_type] => utility [patent_app_number] => 15/720792 [patent_app_country] => US [patent_app_date] => 2017-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37054 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15720792 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12158861 [patent_doc_number] => 20180030127 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-01 [patent_title] => 'ANTI-SERUM ALBUMIN FAB-EFFECTOR MOIETY FUSION CONSTRUCT, AND METHOD OF PREPARING THE CONSTRUCT' [patent_app_type] => utility [patent_app_number] => 15/717528 [patent_app_country] => US [patent_app_date] => 2017-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 18161 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15717528 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12157403 [patent_doc_number] => 20180028668 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-01 [patent_title] => 'Etanercept Formulations Stabilized with Xylitol' [patent_app_type] => utility [patent_app_number] => 15/716005 [patent_app_country] => US [patent_app_date] => 2017-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9628 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15716005 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14534601 [patent_doc_number] => 20190202922 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => EphA5- AND GRP78 BINDING ANTIBODIES AND USES THEREOF AND SELECTION OF PHAGE-DISPLAYED ACCESSIBLE RECOMBINANT TARGETED ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/333898 [patent_app_country] => US [patent_app_date] => 2017-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29401 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -116 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16333898 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12219228 [patent_doc_number] => 20180057586 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-01 [patent_title] => 'ANTI-HEPCIDIN ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/693164 [patent_app_country] => US [patent_app_date] => 2017-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 43731 [patent_no_of_claims] => 62 [patent_no_of_ind_claims] => 39 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15693164 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13689621 [patent_doc_number] => 20170355765 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-14 [patent_title] => TEM8 ANTIBODIES AND THEIR USE IN TREATMENT AND DETECTION OF TUMORS [patent_app_type] => utility [patent_app_number] => 15/680177 [patent_app_country] => US [patent_app_date] => 2017-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39466 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15680177 [rel_patent_id] =>[rel_patent_doc_number] =>)